Výsledky vyhledávání - "Wasif M. Saif"

Implementing a discharge intervention to reduce 30-day readmission and mortality in patients with high-risk cancer: A real-world prospective quality improvement study

Autor: Michelle M. Chin, Ashlie R Jones, Allison Steyl, Patricia Geddie, Zilipah Cruz, Joanne A Bean, Wendy S Cooper, Tek Vu, Daniela Serafimovska, Terra Warner, Akash Nanda, Nicholas George Avgeropoulos, Susan Stallard, Wasif M. Saif, Margo Shoup, Amy Iarrobino Laughlin

Publikováno v: Journal of Clinical Oncology. 40:329-329

329 Background: One in four patients admitted with metastatic cancer are readmitted within 30 days. We created a bundled multipronged intervention to reduce 30-day readmission, unplanned (ED) visits, and mortality among high-risk stage IV cancer pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab44743463ce88928e9eb783edb7a26b
https://doi.org/10.1200/jco.2022.40.28_suppl.329

Zobrazit plný text záznamu

PASS-01: Pancreatic adenocarcinoma signature stratification for treatment–01

Publikováno v: Journal of Clinical Oncology. 40:TPS635-TPS635

TPS635 Background: Over 70% of patients with pancreatic ductal adenocarcinoma (PDAC) present with metastatic disease where the mainstay of treatment is combination chemotherapy. Two pivotal phase III trials showed survival benefit of mFOLFIRINOX (mFF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f612e065b7cbb403a948ec4b6f1a167d
https://doi.org/10.1200/jco.2022.40.4_suppl.tps635

Zobrazit plný text záznamu

Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection

Autor: Carlos López, David Chitty, Bradley Goldberg, Wasif M. Saif, Jeffrey Chi

Publikováno v: Blood

Objective: The global COVID-19 pandemic has posed a major challenge for patients with hematological malignancies undergoing treatment. For patients with acute leukemia and aggressive lymphomas, delaying curative chemotherapy treatments has historical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f60bc6717907c7d6adba89584a6f84f
https://doi.org/10.1182/blood-2020-143124

Zobrazit plný text záznamu

Autor: Jung-In Yang, Bradley Goldberg, Jeffrey Chi, David Chitty, Nina Kohn, Adam Hines, Vernon Wu, Janice Shen, Carlos Lopez, Wasif M. Saif

Publikováno v: Journal of Clinical Oncology. 39:e18626-e18626

e18626 Background: Pts with malignancies are at risk for developing severe complications of COVID-19 with high mortality rate. We retrospectively analyzed COVID-19 related outcomes for hospitalized pts with SMs. Methods: We collected data on hospital

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::357450cc2912eecc67c07cfafa559fa7
https://doi.org/10.1200/jco.2021.39.15_suppl.e18626

Zobrazit plný text záznamu

Duloxetine (DL) in treatment of oxaliplatin-induced peripheral neuropathy (PN)

Autor: Jeffrey Chi, Su Yun Chung, Fatima Fayyaz, Anna Komorowski, Patnita Shepherd, Maura Dillon, Jyothi Jose, Kenneth D. Gold, Wasif M. Saif

Publikováno v: Journal of Clinical Oncology. 39:195-195

195 Background: Oxaliplatin is commonly used to treat many GI cancers, especially colorectal (CRC), pancreatic (PC), and gastric (GC); however, peripheral neuropathy (PN) is the dose-limiting toxicity. Duloxetine (DL) is a second-generation selective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5aa762e488cbc5fc1eef935c0e96bf21
https://doi.org/10.1200/jco.2021.39.3_suppl.195

Zobrazit plný text záznamu

FOLFIRINOX versus sequential 5-FU, oxaliplatin, and irinotecan-based regimens in patients with recurrent pancreatic cancer (rPDAC)

Autor: Hasan Rehman, Carol Lamont, Linda Moriarty, Jeffrey Chi, Jyothi Jose, Nausheen Hakim, Wasif M. Saif

Publikováno v: Journal of Clinical Oncology. 38:e16791-e16791

e16791 Background: There is a paucity of data to guide treatment for rPDAC after curative resection and gemcitabine-based adjuvant chemotherapy. Our aim was to investigate whether combination treatment upfront with all active agents is better than se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8054590d4e1a263cbf48f06849d0bdd
https://doi.org/10.1200/jco.2020.38.15_suppl.e16791

Zobrazit plný text záznamu

Safety and efficacy of biweekly gemcitabine in combination with capecitabine (GemCap) in elderly and frail patients (pts) with resected pancreatic cancer (PC)

Autor: Nausheen Hakim, Antonia Maloney, Jyothi Jose, Linda Moriarty, Wasif M. Saif, Jeffrey Chi, Danielle K. DePeralta, Gary B. Deutsch, Melissa H Smith, Sandeep Anantha, Arvind Rishi, Hasan Rehman, Elliot Newman, Gene F. Coppa, William Nealon

Publikováno v: Journal of Clinical Oncology. 38:4628-4628

4628 Background: ESPAC-4 study showed that GemCap conferred a survival benefit over gemcitabine monotherapy in resected PC patients. ESPAC-4 included patients with median age of 65 years (37-81) and ECOG performance status (PS) of 0 (43%), 1 (54%) an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a2d5ba1dd8dfe22750aad6796b85f4f
https://doi.org/10.1200/jco.2020.38.15_suppl.4628

Zobrazit plný text záznamu

Clinical trial feasibility assessment and start-up tool (CTFAST)

Autor: Amanda Tice, Richard Dima, Wasif M. Saif, Sarah R. Vaiselbuh, Melissa Panzo

Publikováno v: Journal of Clinical Oncology. 38:e14089-e14089

e14089 Background: Selecting the right clinical trials for patients remains a challenging job. The better the match between a clinical trial and the target patient population before conducting a study, the more likely the study will successfully reac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c8c05e2d7aeb8bb5d7d8caacd25f8f9
https://doi.org/10.1200/jco.2020.38.15_suppl.e14089

Zobrazit plný text záznamu

Liver-directed therapy (LDT) and systemic chemotherapy for pancreatic adenocarcinoma with liver metastases (PCLM): Experience of 12 years

Autor: Shreya Prasad Goyal, Craig R. Greben, Wasif M. Saif, Gregory Michael Grimaldi, Jyothi Jose, Kevin P Daly, Igor Lobko, Maged Ghaly

Publikováno v: Journal of Clinical Oncology. 38:e16768-e16768

e16768 Background: PCLM has a poor prognosis with a median survival of ≤6 months. Treatment options are limited as only few patients can undergo curative surgery, therefore locoregional therapies such as LDT offer an adjunct to systemic therapies.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7011577f4d3b9acd96ee06cf2b7aaed
https://doi.org/10.1200/jco.2020.38.15_suppl.e16768

Zobrazit plný text záznamu

A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)

Autor: James J. Harding, Shwu-Huey Liu, Edward Chu, Ghassan K. Abou-Alfa, Yuankai Shi, Wasif M. Saif, Yun Yen, Aiping Tian, Wing Lam, Man-Fung Yuen, Jacqueline Whang-Peng, Yung-Chi Cheng, Shanzhi Gu

Publikováno v: Journal of Clinical Oncology. 38:TPS601-TPS601

TPS601 Background: First-line systemic treatment options for advanced HCC pts are limited to the multi-targeted tyrosine kinase inhibitors, SORA and lenvatinib. Both agents improve outcomes for pts with advanced disease, but are associated with incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01c5c0bde4193d7b7ff8bcaa52887e99
https://doi.org/10.1200/jco.2020.38.4_suppl.tps601

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání